Additional funding opportunities
Research Funding Opportunities
Grants Awarded for Health Sciences Research
| Title | Type | $ Amount |
Activity |
Investigator | Unit | Sponsor | Date |
|---|---|---|---|---|---|---|---|
| Epitope Open-Label Extension Study to Evaluate the Long-Term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children (EPOPEX) | Contract | $173,290.72 | Clinical Trial | Heather Cassell | Asthma/Airway Disease Rsch Ctr | Pharmaceutical Research Associates | 02/2020 |
| FROzEN-AF: Safety and Effectiveness IDE Trial for Boston Scientific's Cryoballoon in the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation | Contract | $122,626.40 | Clinical Trial | Wilber Su | COM Phx Internal Medicine | Boston Scientific Corporation | 07/2020 |
| Phase 2 Window Study of Two Dose Levels of SAR439859 (SERD) Versus Letrozole in Newly Diagnosed Pre-Operative Post-Menopausal Patients with ER Positive, HER2 Negative Primary Breast Cancer | Contract | $95,384.00 | Clinical Trial | Nova Foster | Cancer Center Division | Sanofi-Aventis United States Incorporated | 09/2020 |
| A First-in-Human Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 in Adults with Advanced Solid Malignancies | Contract | $468,451.00 | Clinical Trial | Alejandro Recio Boiles | Cancer Center Division | Atreca, Inc. | 10/2020 |
| A Phase 1b/2 Study of AST-008 Combined with Pembrolizumab or Cemiplimab in Patients with Advanced Solid Tumors | Contract | $157,802.00 | Clinical Trial | Montaser Shaheen | Cancer Center Division | Exicure, Inc. | 06/2020 |
| FLowTriever All-Comer Registry for Patient Safety and Hemodynamics (FLASH) | Contract | $125,613.76 | Clinical Trial | Christopher Goettl | COM Phx Radiology | Inari Medical | 02/2020 |
| Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (ICECAP) | Cooperative Agreement | $383,000.00 | Clinical Trial | Jarrod Mosier | Dept of Emergency Medicine | University of Michigan | 07/2020 |
| SWOG Network Group Operations Center of the NCTN | Cooperative Agreement | $900,000.00 | Clinical Trial | Daniel Persky | Cancer Center Division | Oregon Health and Science University | 09/2020 |
| A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-COV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients with COVID-19 | Contract | $254,412.60 | Clinical Trial | Billie Bixby | Medicine | Regeneron Pharmaceuticals, Inc | 10/2020 |
| A Phase II Trial of PET-Directed Therapy using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, with or without Brentuximab Vedotin Plus Nivolumab, Foll | Contract | $40,100.00 | Clinical Trial | Abhijeet Kumar | Cancer Center Division | Mayo Foundation for Medical Education and Research (Mayo Clinic) | 06/2020 |
| Phase 1/1b Multicenter, Open-Label, First-in-Human Dose Escalation and Dose Expansion Study to Assess Safety and Tolerability of Orally Administered PMD-026 in Patients with Metastatic Breast Cancer w | Contract | $100,897.00 | Clinical Trial | Pavani Chalasani | Cancer Center Division | Phoenix Molecular Designs (Canada) | 02/2020 |
| SEER-Lung: A Prospective Blood Sample Collection Study to Develop and Validate a Panel of Protein-based Biomarkers in Patients with Pulmonary Nodules | Contract | $23,319.00 | Clinical Trial | Raed Alalawi | COM Phx Internal Medicine | Seer, Inc. | 07/2020 |
| Web-based Physical Activity Intervention for Children with ALL | Grant | $175,000.00 | Clinical Trial | Holly Pariury | Cancer Center Division | Children's Hospital of Philadelphia | 09/2020 |
| A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome (ARDS) | Contract | $167,627.92 | Clinical Trial | Christian Bime | Medicine | Kinevant Sciences, Inc. | 10/2020 |
| A Phase III, Multicenter, Open-Label, Extension Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PARI... | Contract | $432,030.00 | Clinical Trial | Ramachandra Sista | COM Phx Internal Medicine | Covance, Incorporated | 06/2020 |
| SWOG NCORP Research Base | Cooperative Agreement | $54,000.00 | Clinical Trial | Daniel Persky | Cancer Center Division | Oregon Health and Science University | 07/2020 |
| A Phase 2 Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-cell Lymphoma (PTCL) in Adults Age 60 and Above | Contract | $147,691.00 | Clinical Trial | Daniel Persky | Cancer Center Division | Seattle Genetics, Incorporated | 05/2020 |
| A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-Tumor Activity of ABBV-321 in Subjects with Advanced Solid Tumors Associated with Overexpression of the Epidermal Growth Factor Recept | Contract | $854,975.00 | Clinical Trial | Hani Babiker | Cancer Center Division | AbbVie Incorporated | 10/2020 |
| A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with Either Durvalumab Monotherapy or Durvalumab Plus Bevacizumab | Contract | $208,612.70 | Clinical Trial | Gregory Woodhead | Cancer Center Division | Astrazeneca | 06/2020 |
| A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants with Previously Treated Locally Advanced/Metastatic or Surgically Unresectable.. | Contract | $171,440.00 | Clinical Trial | Aaron Scott | Cancer Center Division | Incyte Corporation | 05/2020 |
| A Phase 2 Randomized Study of Adjuvant Immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma | Contract | $206,150.52 | Clinical Trial | Montaser Shaheen | Cancer Center Division | PPD Investigator Services, LLC. | 10/2020 |
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Patients with COVID-19 Pneumonia | Contract | $3,236,387.50 | Clinical Trial | Sachin Chaudhary | Medicine | Syneos Health | 06/2020 |
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects | Contract | $79,672.00 | Clinical Trial | Ramachandra Sista | COM Phx Internal Medicine | Vertex Pharmaceuticals, Incorporated | 05/2020 |
| A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine in Participants Undergoing Surgeries that Include a Bowel Resection or Bowel Transection | Contract | $586,018.76 | Clinical Trial | Bellal Joseph | Surgery | Shionogi Inc | 10/2020 |
| A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting with Community Acquired... | Contract | $593,373.00 | Clinical Trial | John Galgiani | Valley Fever Ctr for Excellnc | Duke University | 06/2020 |